-
-
Genetic Engineering & Biotechnology News (June 9, 2023) AI Takes On Drug Discovery
Artificial intelligence appears poised to transform many aspects of our lives, and drug discovery is no exception. By removing much of the trial and error from drug discovery, AI reveals new targets and tactics for treating diseases.
Genetic Engineering & Biotechnology News (June 8, 2023) Experimental Cancer Drug Slows Inflammation in Animal Models of Heart Disease
A study in mice and in rabbits suggests that an experimental drug called saracatinib, which has already been tested as a potential treatment for cancer, lung, and Alzheimer’s disease, may slow the progression of atherosclerosis that leads to heart disease. To identify the drug as a potential candidate for atherosclerotic cardiovascular disease (ASCVD) investigators led by a team at NYU Grossman School of Medicine developed a strategy that combines systems immunology-driven-drug repurposing, with a functional screen using human samples.
Becker’s Health IT (June 6, 2023) Mayo to use AI-powered digital pathology to support drug development
Rochester, Minn.-based Mayo Clinic BioPharma Diagnostics has partnered with artificial intelligence-powered spatial biology company Nucleai to support drug development using AI. Under the partnership, Mayo Clinic’s multimodal datasets, laboratories and clinical expertise will combine with Nucleai’s AI platform to develop new offerings for biomarker discovery and validation, end-to-end spatial biology testing and algorithm deployment for clinical trials and diagnostic use, according to a June 4 press release from Nucleai. The aim is for both entities to create new digital pathology solutions, technologies and services to support drug development and clinical practice.
-
- You must be logged in to reply to this topic.